SPTBN2 is a gene that encodes the protein Spectrin Beta, Non-Erythrocytic 2, also known as beta-III spectrin. This protein is a member of the spectrin superfamily, a group of cytoskeletal proteins critical for maintaining cell shape, membrane stability, and organization of various cellular processes.
Function
The SPTBN2 gene produces beta-III spectrin, a key component of the spectrin-actin cytoskeleton. This network of proteins is located beneath the cell membrane and provides essential structural support to cells. Beta-III spectrin plays a crucial role in the central nervous system, particularly in the cerebellum. It interacts with other proteins, such as ankyrin, to form a stable scaffold essential for neuronal architecture, synaptic integrity, and the proper functioning of Purkinje cells, which are vital for motor coordination and balance.
Tissue Distribution
SPTBN2 is widely expressed in various tissues throughout the body, but it is particularly abundant in the brain. High levels are found specifically in cerebellar Purkinje cells, highlighting its critical role in cerebellar function. It is also detected in other tissues, including the heart, kidney, and lung, suggesting broader, though less characterized, roles beyond the nervous system.
Clinical Significance
Mutations in the SPTBN2 gene are definitively linked to Spinocerebellar Ataxia Type 5 (SCA5). SCA5 is a rare, autosomal dominant neurodegenerative disorder characterized by a progressive loss of coordination (ataxia), affecting gait, speech, and eye movements. The disease primarily results from the degeneration of Purkinje cells in the cerebellum, where the beta-III spectrin protein is highly concentrated and critical for function. The mutations lead to a defective or unstable spectrin protein, disrupting the cytoskeletal organization within these neurons and ultimately impairing cerebellar function.
See Also
- Spectrin
- Spinocerebellar Ataxia
- Purkinje Cell